1. Repository of OAI
  2. ΑΠΟΘΕΤΗΡΙΟ "ΟΛΥΜΠΙΑΣ"
  3. Σχολή Επιστημών Υγείας
  4. Τμήμα Ιατρικής
  5. Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ
Ελληνικά   English  
Please use this identifier to cite or link to this item: https://olympias.lib.uoi.gr/jspui/handle/123456789/19314
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLevin, V. A.en
dc.contributor.authorUhm, J. H.en
dc.contributor.authorJaeckle, K. A.en
dc.contributor.authorChoucair, A.en
dc.contributor.authorFlynn, P. J.en
dc.contributor.authorYung, W. K. A.en
dc.contributor.authorPrados, M. D.en
dc.contributor.authorBruner, J. M.en
dc.contributor.authorChang, S. M.en
dc.contributor.authorKyritsis, A. P.en
dc.contributor.authorGleason, M. J.en
dc.contributor.authorHess, K. R.en
dc.date.accessioned2015-11-24T18:58:49Z-
dc.date.available2015-11-24T18:58:49Z-
dc.identifier.issn1078-0432-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/19314-
dc.rightsDefault Licence-
dc.subjectAdolescenten
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntineoplastic Combined Chemotherapy Protocols/*administration &en
dc.subjectdosage/*therapeutic useen
dc.subjectBrain Neoplasms/*drug therapy/mortality/*radiotherapyen
dc.subjectCisplatin/*administration & dosageen
dc.subjectCyclophosphamide/*administration & dosageen
dc.subjectDisease-Free Survivalen
dc.subjectDose-Response Relationship, Drugen
dc.subjectEflornithine/*administration & dosageen
dc.subjectFemaleen
dc.subjectGlioblastoma/*drug therapy/mortality/*radiotherapyen
dc.subjectHumansen
dc.subjectLomustine/*administration & dosageen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectProcarbazine/*administration & dosageen
dc.subjectProspective Studiesen
dc.subjectTime Factorsen
dc.subjectVincristine/*administration & dosageen
dc.subjectVindesine/*administration & dosageen
dc.titlePhase III randomized study of postradiotherapy chemotherapy with alpha-difluoromethylornithine-procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, vincristine (DFMO-PCV) versus PCV for glioblastoma multiformeen
heal.typejournalArticle-
heal.type.enJournal articleen
heal.type.elΆρθρο Περιοδικούel
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/11051233-
heal.identifier.secondaryhttp://clincancerres.aacrjournals.org/content/6/10/3878.full.pdf-
heal.languageen-
heal.accesscampus-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.publicationDate2000-
heal.abstractAlthough the efficacy of the nitrosourea-based combination chemotherapy procarbazine, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosurea, and vincristine (PCV) has been previously demonstrated in the setting of anaplastic/intermediate-grade gliomas, the benefit for glioblastoma patients remains unproven. In the current study, we sought to determine whether the addition of alpha-difluoromethylornithine (eflornithine), an inhibitor of ornithine decarboxylase, which has shown encouraging results in the setting of recurrent glioma patients, to a nitrosourea-based therapy (PCV) would constitute a more effective adjuvant therapy in the treatment of glioblastoma multiforme patients in the postradiation therapy setting. Following conventional radiation therapy, 272 glioblastoma (GBM) patients were randomized to receive either alpha-difluoromethylornithine-PCV (DFMO-PCV; 134 patients) or PCV alone (138 patients), with survival and time to tumor progression being the primary endpoints. The starting dosage of DFMO was 3.0 g/m2 p.o. q8h for 14 days before and after treatment with N-(2-chloroethyl)-N-cyclohexyl-N-nitrosurea; PCV was administered as previously described1. Clinical and radiological (Gadolinium-enhanced MRI) follow-ups were nominally at the end of each 6 or 8 week cycle (PCV at 6 weeks; DFMO-PCV at 8 weeks). Laboratory evaluations for hematologic and other adverse effects were at 2 week intervals. There was no difference in median survival or median time-to-tumor progression between the two treatment groups, as measured from day of commencement of postradiotherapy chemotherapy [MS (months): DFMO-PCV, 10.5; Overall survival, as measured from time of tumor diagnosis at first surgery, was 13.3 and 14.2 months at the median and 6.2 and 8.7% at 5 years, respectively, for the DFMO-PCV and PCV arms. The treatment effect was unchanged after adjustment for age, performance status (KPS), extent of surgery, and other factors using the multivariate Cox proportional hazard model. Adverse effects associated with DFMO consisted of gastrointestinal (diarrhea nausea/vomiting), cytopenias, and minimal ototoxicity (limited to tinnitus) at the dose range tested. The addition of DFMO to the nitrosourea-based PCV regimen in this phase III study demonstrated no additional benefit in glioblastoma patients, underscoring the resistance of glioblastoma multiforme tumors to alkylating agents. For patients with anaplastic (intermediate grade) gliomas, in which the previously demonstrated benefit of post-radiation chemotherapy is more substantial, the evaluation of DFMO-PCV vs. PCV is still ongoing and hopefully will yield more encouraging results.en
heal.journalNameClin Cancer Resen
heal.journalTypepeer-reviewed-
heal.fullTextAvailabilityTRUE-
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ

Show simple item record
Files in This Item:
File Description SizeFormat 
Levin-2000-Phase III randomized.pdf119.21 kBAdobe PDFView/Open    Request a copy
Show simple item record  


This item is licensed under a Creative Commons License Creative Commons